Goldman Sachs Maintains Neutral on GeneDx Hldgs, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on GeneDx Hldgs (NASDAQ:WGS) and lowered the price target from $8 to $7.
August 09, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has maintained a Neutral rating on GeneDx Hldgs and lowered the price target from $8 to $7.
The news directly pertains to GeneDx Hldgs (NASDAQ:WGS) as Goldman Sachs has maintained a Neutral rating on the company and lowered the price target. This could potentially impact investor sentiment and the stock's price in the short term, although the Neutral rating suggests that the overall outlook for the stock remains unchanged.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100